MUC1 expression in primary breast cancer: the effect of tamoxifen treatment
MUC1 expression in primary breast cancer: the effect of tamoxifen treatment
复制标题
DOI：
10.1023/a:1017955726902
复制
发表时间：
2001-06-01
影响因子：
3.8
通讯作者：
Pearson, JP
中科院分区：
文献类型：
--
作者：
Hanson, JM;Browell, DA;Pearson, JP
这是一项非随机化单机构回顾性研究。从一组在活检和手术之间接受了3周他莫昔芬新辅助治疗的患者中获得了46个冷冻肿瘤样本库。从一组未接受他莫昔芬新辅助治疗的合并治疗的原发性乳腺癌患者中随机选择51例比较标本。标本选择不基于预后因素：激素受体状态、患者年龄或绝经状态。流式细胞术检测MUC 1表达和细胞周期分布。比较S期、MUC 1阳性和MUC 1阴性细胞比例。在他莫昔芬治疗3周后，表达MUC 1的细胞百分比较低，为18.2%对28.5%（p = 0.03，Mann-Whitney），并且在他莫昔芬治疗后，MUC 1表达水平较低，为31，519分子/细胞对39，387分子/细胞（p = 0.04，Mann-Whitney）。MUC 1阳性细胞，无论治疗组如何，具有更大比例的细胞处于细胞周期的S期，27.9%对16.8%（p = 0.0004，Mann-Whitney），并显示更多的非整倍性病例，80.65%对42.6%（p < 0.0001）。用他莫昔芬治疗3周的原发性肿瘤中的MUC 1水平低于未接受他莫昔芬治疗的对照组。MUC 1作为一种中间生物标志物在治疗和预后评估中的作用值得进一步研究。
This was a non-randomised single institution retrospective study. Forty-six banked frozen tumour specimens were obtained from a group of patients who had undergone 3 weeks of neoadjuvant treatment with tamoxifen between biopsy and surgery. Fifty-one comparison specimens were randomly selected from a group of concomitantly treated primary breast cancer patients who did not receive neoadjuvant tamoxifen. Specimen selection was not based on prognostic factors: hormone receptor status, patient age, or menopausal status. MUC1 expression and cell cycle distribution were assessed by flow cytometry. S-phase, fraction of MUC1 positive and MUC1 negative cells were compared. A lower percentage of cells expressed MUC1 following 3-week tamoxifen treatment 18.2% versus 28.5% (p = 0.03, Mann-Whitney) and lower levels of MUC1 expression were seen following tamoxifen treatment 31,519 molecules/cell versus 39,387 (p = 0.04, Mann-Whitney). MUC1 positive cells, irrespective of treatment group, had a greater proportion of cells in S-phase of the cell cycle 27.9% versus 16.8% (p = 0.0004, Mann-Whitney) and demonstrated more cases of aneuploidy 80.65% versus 42.6% (p < 0.0001). MUC1 levels in primary tumours treated neoadjunctively with 3 weeks of tamoxifen were lower than a comparison group which did not receive tamoxifen. MUC1 should be explored further as an intermediate biomarker for assessment of treatment and prognosis.